(HealthDay)—California researchers are testing whether an oral vaccine offers similar or better protection than current COVID-19 shots.
Existing vaccines promote production of antibodies to the spike protein on the surface of the coronavirus that causes COVID-19, but the ImmunityBio T cell oral vaccine targets the globe in the middle of the virus, a part that is less prone to mutation, according to scientists. “And the value of doing so is that we generate killer T cells,” ImmunityBio founder and Executive Chairman Patrick Soon-Shiong, M.D., told CBS News.
The ImmunityBio researchers believe they may be able to create long-term protection by generating both antibodies and killer T cells.
CBS News Article
Copyright © 2021 HealthDay. All rights reserved.
Oral COVID-19 vaccine being tested (2021, April 8)
retrieved 8 April 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.